¼¼°èÀÇ °íºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå
Large Molecule Injectable Drugs
»óǰÄÚµå : 1794416
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °íºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀº 2030³â±îÁö 7,807¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 4,761¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °íºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 8.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 7,807¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Á¤¸ÆÁÖ»ç´Â CAGR 8.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4,559¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±ÙÀ°ÁÖ»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 1,297¾ï ´Þ·¯, Áß±¹Àº CAGR 13.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °íºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀº 2024³â¿¡ 1,297¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀ» 13.2%·Î, 2030³â±îÁö ¿¹Ãø ½ÃÀå ±Ô¸ð 1,685¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.4%¿Í 8.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °íºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°íºÐÀÚ ÁÖ»çÁ¦°¡ Çö´ë Ä¡·áÁ¦ÀÇ Áß½ÉÀÌ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°íºÐÀÚ ÁÖ»çÁ¦´Â Á¾Á¾ »ý¹°Á¦Á¦¶ó°í ºÒ¸®´Â °íºÐÀÚ ÁÖ»çÁ¦´Â ³ôÀº ƯÀ̼º, È¿´É, ÀúºÐÀÚ ÀǾàǰÀÌ Á¾Á¾ È¿°úÀûÀ¸·Î Ç¥ÀûÈ­ÇÒ ¼ö ¾ø´Â º¹ÀâÇÑ Áúº´¿¡ ´ëóÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ Çö´ë ÀÇÇп¡ ÇʼöÀûÀÎ Á¸Àç°¡ µÇ¾ú½À´Ï´Ù. ´ÜŬ·Ð Ç×ü, ÆéƼµå, ÀçÁ¶ÇÕ ´Ü¹éÁúÀ» Æ÷ÇÔÇÑ ÀÌ·¯ÇÑ °íºÐÀÚ´Â Å©±â¿Í º¹À⼺À¸·Î ÀÎÇØ ¼ÒÈ­ È¿¼Ò¿¡ ÀÇÇØ ºÐÇØµÇ´Â °æ±¸ Åõ¿©¿¡ ÀûÇÕÇÏÁö ¾Ê±â ¶§¹®¿¡ º¸Åë Áֻ縦 ÅëÇØ Åõ¿©µË´Ï´Ù. »ý¹°Á¦Á¦´Â °Ç°­ÇÑ Á¶Á÷ÀÇ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ½À´Ï´Ù. ·ù¸¶Æ¼½º °üÀý¿°, ´Ù¹ß¼º °æÈ­Áõ, ¿°Áõ¼ºÀåÁúȯ µî ÀÚ°¡¸é¿ªÁúȯµµ Ç¥ÀûÈ­µÈ ÁÖ»çÁ¦ ´öºÐ¿¡ Ä¡·á ¼ºÀûÀÌ Å©°Ô °³¼±µÇ¾ú½À´Ï´Ù. ¸¸¼ºÁúȯ°ú »ýȰ½À°üº´ Áõ°¡µµ »ý¹°Á¦Á¦°¡ Á¦°øÇÒ ¼ö ÀÖ´Â Àå±âÀûÀ̰í ÀϰüµÈ Ä¡·á¸¦ ÇÊ¿ä·Î Çϴ ȯÀÚµé ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷Àº »õ·Î¿î »ý¹°Á¦Á¦ÀÇ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Áö¼ÓÇϰí ÀÖÀ¸¸ç, µ¶Æ¯ÇÑ ÀÛ¿ë±âÀüÀ¸·Î ÀÎÇØ ±ÔÁ¦´ç±¹°ú ½ÃÀåÀÇ ½ÂÀÎÀ» ¹Þ±â ½±µµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÀǾàǰÀº º¹ÀâÇϹǷΠÁ¦³×¸¯ ÀǾàǰÀÇ °æÀïÀ» ¸·´Â À庮ÀÌ µÇ°í, ±â¾÷Àº Áö¼ÓÀûÀÎ ½ÃÀå µ¶Á¡À» ÅëÇØ ÅõÀÚ±ÝÀ» ȸ¼öÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, °íºÐÀÚ ÁÖ»çÁ¦´Â Ä¡·á ¹üÀ§¸¦ È®´ëÇÒ »Ó¸¸ ¾Æ´Ï¶ó Á¦¾à »ê¾÷ÀÇ °æÁ¦ ¹× Çõ½Å ¸ðµ¨À» À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÌ »ý¹°Á¦Á¦ Àü´Þ°ú ȯÀÚ °æÇèÀ» ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀ¸·Î »ý¹°Á¦Á¦ °ü·Ã Àü´Þ ½Ã½ºÅÛ°ú ȯÀÚ °æÇèÀÌ Å©°Ô °³¼±µÇ°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ÁÖ»ç´Â ÁÖ·Î ÀÓ»ó ÇöÀå¿¡¼­ ÀÌ·ç¾îÁ³Áö¸¸, ÀÚµ¿ÁÖ»ç±â, ÇÁ¸®ÇÊµå ½Ã¸°Áö µî ¾ÈÀüÇÏ°í Æí¸®ÇÑ °¡Á¤³» ÀÚ°¡Åõ¿©¸¦ °¡´ÉÇÏ°Ô Çϴ ÷´Ü Àü´Þ ÀåÄ¡·Î Á¡Â÷ º¸¿ÏµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡´Â Á¤È®ÇÑ Åõ¾àÀ» º¸ÀåÇϰí, Åõ¾à ¿À·ùÀÇ À§ÇèÀ» ÁÙÀ̸ç, Ä¡·á ¿ä¹ýÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ã۵µ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. Áö¼ÓÇü ÁÖ»çÁ¦ ¹× ¼­¹æÇü ½Ã½ºÅÛ°ú °°Àº ¾à¹° Á¦Á¦ÀÇ Çõ½ÅÀº ÁÖ»çÀÇ ºóµµ¸¦ ÁÙÀ̰í ȯÀÚÀÇ ÆíÀǼº°ú ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯È÷ Á¡¼º ¶§¹®¿¡ Ç¥ÁØ ÁÖ»ç±â·Î´Â È¿°úÀûÀ¸·Î Åõ¿©ÇÒ ¼ö ¾ø´Â »ý¹°Á¦Á¦ÀÇ °æ¿ì, Àå½Ã°£¿¡ °ÉÃÄ ´Ù·®À¸·Î ÇÇÇÏ Åõ¿©ÇÒ ¼ö ÀÖ´Â ¿þ¾î·¯ºí ÁÖ»ç±â°¡ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ ±â¼úµµ Åõ¾à ¾Ë¸², ÁÖ»ç ÃßÀû, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿ÍÀÇ µ¥ÀÌÅÍ °øÀ¯ µîÀÇ ±â´ÉÀ» Á¦°øÇϱâ À§ÇØ Åõ¾à Ç÷§Æû¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´É °­È­´Â Ä¡·á °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ÀÇ·á ÀÎÇÁ¶óÀÇ ºÎ´ãÀ» ÁÙ¿©ÁÖ´Â ºÐ»êÇü Áø·á ¸ðµ¨·ÎÀÇ ÀüȯÀ» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÏȸ¿ë ½Ã½ºÅÛ ¹× ¼¼Æ÷¹è¾ç ÃÖÀûÈ­ µîÀÇ Á¦Á¶ ±â¼úÀº »ý¹°Á¦Á¦ Á¦Á¶ÀÇ È®À强°ú È¿À²¼ºÀ» Çâ»ó½ÃÄÑ Àü ¼¼°è ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀº Ä¡·á ¿µ¿ª Àü¹Ý¿¡ °ÉÃÄ »ý¹°Á¦Á¦°¡ °³¹ßµÇ°í, Á¦°øµÇ°í, ȯÀÚ°¡ °æÇèÇÏ´Â ¹æ½ÄÀ» Å©°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

»ý¹°Á¦Á¦ ÁÖ»çÁ¦ÀÇ ¼¼°è ¼ö¿ä¸¦ Çü¼ºÇÏ´Â ½ÃÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

¸î °¡Áö ½ÃÀå ¿äÀÎÀÌ °íºÐÀÚ ÁÖ»çÁ¦ÀÇ ¼¼°è È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ°ú Èñ±ÍÁúȯÀÇ ¼¼°èÀû È®»êÀº ƯÈ÷ ¸é¿ªÁúȯ°ú ÅðÇ༺ Áúȯ¿¡ Ãë¾àÇÑ °í·ÉÈ­ »çȸ¿¡¼­ °¡Àå °­·ÂÇÑ ¼ö¿ä ÃËÁø¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀº ±Þ¼º±â ÀÇ·á¿¡¼­ ¸¸¼ºÁúȯ °ü¸®·Î Á¡Â÷ ÀüȯµÇ°í ÀÖÀ¸¸ç, ¿©±â¼­ »ý¹°Á¦Á¦´Â Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ±×µ¿¾È °í¼Òµæ ±¹°¡¿¡ ±¹ÇѵǾî ÀÖ´ø ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ Æø³ÐÀº Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯(»ý¹°Á¦Á¦ÀÇ À¯»çÇÏÁö¸¸ µ¿ÀÏÇÏÁö ¾ÊÀº Á¦Ç°)µµ ½ÃÀå¿¡ ÁøÀÔÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ºí·Ï¹ö½ºÅÍ »ý¹°Á¦Á¦ÀÇ Æ¯Çã°¡ ¸¸·áµÈ ÈÄ ´õ Àú·ÅÇÑ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ȯÀÚ Á¢±Ù¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ÁöºÒÀÚ¿Í ±ÔÁ¦±â°üÀº °¡Ä¡ ±â¹Ý ÀÇ·á¿Í ½ÇÁ¦ °á°ú¿¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀ̰í ÀÖÀ¸¸ç, Á¦¾à»çµéÀÌ ÁÖ»çÁ¦ »ý¹°Á¦Á¦ÀÇ ÀÓ»óÀû, °æÁ¦Àû °¡Ä¡¸¦ ÀÔÁõÇÒ °ÍÀ» Ã˱¸Çϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷°ú ´ëÇü Á¦¾à»ç °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½Ê, ¶óÀ̼±½Ì °è¾à, ÇÕº´Àº ¿¬±¸°³¹ß, À¯ÅëÀ» À§ÇÑ ÀÚ¿øÀ» ÅëÇÕÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °øÁß º¸°Ç ÇÁ·Î±×·¥ ¹× ºñ¿µ¸®´Üüµéµµ HIV, °£¿°, ƯÁ¤ ¼Ò¾Æ Áúȯ°ú °°Àº Áúº´¿¡ ´ëóÇϱâ À§ÇØ ÁÖ»ç °¡´ÉÇÑ »ý¹°Á¦Á¦¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ »ý¹°Á¦Á¦ ÁÖ»çÁ¦ÀÇ ¼¼°è º¸±ÞÀÌ ÁøÇàµÇ¾î °æÀïÀûÀ̸鼭µµ ¸Å¿ì Çõ½ÅÀûÀÎ ½ÃÀå ȯ°æÀÌ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù.

°íºÐÀÚ ÁÖ»çÁ¦ ¼¼°è ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

¼¼°è °íºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Çõ½Å, ÁøÈ­ÇÏ´Â ÇコÄÉ¾î ´ÏÁî, ±ÔÁ¦ ȯ°æÀÇ º¯È­ µîÀÇ º¹ÇÕÀûÀÎ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. »ý¸í°øÇаú ºÐÀÚ°øÇÐÀÇ ¹ß´Þ·Î ÀÌÀü¿¡´Â Ä¡·á°¡ ¾î·Á¿ü´ø Áúº´¿¡ Ź¿ùÇÑ È¿°ú¸¦ ¹ßÈÖÇϴ ÷´Ü Ç¥ÀûÄ¡·áÁ¦ °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, Èñ±ÍÀ¯ÀüÁúȯÀÇ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ ¸é¿ª¹ÝÀÀÀ» Á¶ÀýÇϰųª °á¼Õ ´Ü¹éÁúÀ» ´ëüÇÒ ¼ö ÀÖ´Â »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀçÅÃÄ¡·á¿Í ÀÚ°¡ Åõ¾à ¼±È£ µî ȯÀÚ ÇൿÀÇ º¯È­, ƯÈ÷ Àü´Þ ÀåÄ¡ÀÇ »ç¿ë ÆíÀǼº ¹× ¹®ÅÎÀÌ ³·¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº »õ·Î¿î »ý¹°Á¦Á¦¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ½ÂÀÎ °æ·Î¸¦ °£¼ÒÈ­ÇÏ¿© ½ÅÁ¦Ç° Ãâ½Ã ¼Óµµ¸¦ °¡¼ÓÈ­ÇÏ°í °æÀïÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº ÄݵåüÀÎ ¹°·ù¿¡¼­ ÀÓ»óÀÇ»ç ±³À°¿¡ À̸£±â±îÁö »ý¹°Á¦Á¦ÀÇ Ä¡·á ÀÎÇÁ¶ó¿¡ ÅõÀÚÇÏ¿© ÀÌ·¯ÇÑ ÁÖ»çÁ¦ÀÇ ±¤¹üÀ§ÇÑ Åõ¿©¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. Àα¸Åë°èÇÐÀû Ãß¼¼, ƯÈ÷ Àα¸ °í·ÉÈ­¿Í Æò±Õ¼ö¸í Áõ°¡·Î ÀÎÇØ ¸¸¼ºÁÖ»ç ¿ä¹ýÀÇ Àå±âÀûÀÎ »ç¿ëÀÚÃþÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à»çµéÀº º¹ÀâÇÑ Ä¡·á ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ Ç×ü¾à¹°Á¢ÇÕü, ¼¼Æ÷ ±â¹Ý ÁÖ»çÁ¦ µî Â÷¼¼´ë »ý¹°Á¦Á¦·Î ÆÄÀÌÇÁ¶óÀÎÀ» ´Ù¾çÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè°ú Á¦Á¶ÀÇ ¼¼°èÈ­·Î ÀÎÇØ °ø±Þ¸Á È¿À²¼º°ú ½ÃÀå µµ´Þ ¹üÀ§°¡ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç ¿äÀÎÀ¸·Î ÀÎÇØ °­·ÂÇÏ°í ºü¸£°Ô ÁøÈ­ÇÏ´Â »ýŰ谡 ±¸ÃàµÇ°í ÀÖÀ¸¸ç, °íºÐÀÚ ÁÖ»çÁ¦´Â ¼¼°è ÇコÄɾîÀÇ ¹Ì·¡¿¡¼­ Á¡Á¡ ´õ Áß½ÉÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯Çü(Á¤¸ÆÁÖ»ç, ±ÙÀ°ÁÖ»ç, ÇÇÇÏ ÁÖ»ç), ÃÖÁ¾ »ç¿ë(º´¿ø ¾à±¹ ÃÖÁ¾ »ç¿ë, ¼Ò¸Å ¾à±¹ ÃÖÁ¾ »ç¿ë, E-Commerce ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Large Molecule Injectable Drugs Market to Reach US$780.7 Billion by 2030

The global market for Large Molecule Injectable Drugs estimated at US$476.1 Billion in the year 2024, is expected to reach US$780.7 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Intravenous Injections, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$455.9 Billion by the end of the analysis period. Growth in the Muscle Injections segment is estimated at 9.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$129.7 Billion While China is Forecast to Grow at 13.2% CAGR

The Large Molecule Injectable Drugs market in the U.S. is estimated at US$129.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$168.5 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Large Molecule Injectable Drugs Market - Key Trends & Drivers Summarized

Why Are Large Molecule Injectables Becoming Central to Modern Therapeutics?

Large molecule injectable drugs, often referred to as biologics, have become an integral part of contemporary medicine due to their high specificity, potency, and ability to address complex diseases that small molecule drugs often cannot target effectively. These macromolecules, which include monoclonal antibodies, peptides, and recombinant proteins, are typically administered via injection because their size and complexity make them unsuitable for oral delivery, where digestive enzymes would degrade them. One of the key areas where these drugs have demonstrated immense impact is in oncology, where biologics can target cancer cells with minimal damage to healthy tissue. Similarly, autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease have seen substantial improvements in treatment outcomes thanks to targeted injectable biologics. The rise in chronic and lifestyle-related conditions has also driven demand, as patients require long-term, consistent therapies that biologics can provide. Biopharmaceutical companies continue to invest heavily in R&D for novel biologics, which are more likely to receive regulatory and market approval due to their unique mechanisms of action. The complexity of these drugs also creates a barrier to generic competition, allowing companies to recoup investments through sustained market exclusivity. As a result, large molecule injectables are not only expanding in therapeutic scope but are also reshaping the economics and innovation models within the pharmaceutical industry.

How Is Technology Enhancing Delivery and Patient Experience in Biologic Therapies?

Technological advancements are significantly improving the delivery systems and patient experience associated with large molecule injectable drugs. Traditional injections, often administered in clinical settings, are gradually being complemented by advanced delivery devices such as auto-injectors and prefilled syringes that enable safe and convenient self-administration at home. These devices are designed to ensure precise dosing, reduce the risk of administration errors, and improve adherence to treatment regimens. Innovations in drug formulation, including long-acting injectables and sustained-release systems, are reducing the frequency of injections, thereby increasing patient comfort and compliance. Furthermore, wearable injectors that can deliver high volumes subcutaneously over an extended period are gaining traction, particularly for biologics that cannot be effectively delivered through standard syringes due to their viscosity. Digital health technologies are also being integrated into delivery platforms, offering features such as dose reminders, injection tracking, and data sharing with healthcare providers. These enhancements not only improve therapeutic outcomes but also support a shift toward decentralized care models that reduce the burden on healthcare infrastructure. In addition, manufacturing technologies such as single-use systems and cell culture optimization are increasing the scalability and efficiency of biologic drug production, which helps to meet growing global demand. These technological strides are transforming how biologics are developed, delivered, and experienced by patients across therapeutic areas.

What Market Forces Are Reshaping Global Demand for Biologic Injectables?

Several market forces are converging to drive the global expansion of large molecule injectable drugs. The increasing global prevalence of chronic and rare diseases is one of the strongest demand drivers, especially in aging populations that are more susceptible to immunological and degenerative disorders. Healthcare systems are gradually shifting from acute care to chronic disease management, where biologics play a critical role. The rise in healthcare expenditure, especially in emerging markets, is enabling broader access to advanced therapies that were previously limited to high-income countries. Biosimilars, which are highly similar but not identical versions of original biologic drugs, are also entering the market and expanding patient access by offering more affordable options, especially after patent expirations of blockbuster biologics. At the same time, payer and regulatory bodies are placing greater emphasis on value-based care and real-world outcomes, encouraging pharmaceutical companies to demonstrate the clinical and economic value of their injectable biologics. Strategic partnerships, licensing agreements, and mergers between biotech firms and larger pharmaceutical companies are further catalyzing market growth by pooling resources for research, development, and distribution. Public health programs and non-profit organizations are also increasing investments in injectable biologics to address diseases like HIV, hepatitis, and certain pediatric conditions. These evolving market dynamics are broadening the global footprint of biologic injectables and shaping a competitive but highly innovative commercial landscape.

What Is Driving the Growth in the Global Large Molecule Injectable Drugs Market?

The growth in the global large molecule injectable drugs market is driven by a combination of technological innovation, evolving healthcare needs, and shifting regulatory landscapes. Advances in biotechnology and molecular engineering have enabled the development of highly targeted therapies that offer superior efficacy for conditions previously considered difficult to treat. Increasing incidence of cancers, autoimmune disorders, and rare genetic diseases has led to a rising demand for biologics that can modulate immune responses or replace deficient proteins. Changing patient behavior, including a preference for home-based care and self-administration, is also fueling the market, particularly as delivery devices become more user-friendly and less intimidating. Regulatory agencies have streamlined approval pathways for both novel biologics and biosimilars, accelerating the pace of new product launches and encouraging competition. Health systems are investing in biologic treatment infrastructure, from cold chain logistics to clinician training, to support widespread administration of these injectables. Demographic trends, especially population aging and increased life expectancy, are expanding the long-term user base for chronic injectable therapies. Additionally, pharmaceutical firms are diversifying pipelines with next-generation biologics, such as antibody-drug conjugates and cell-based injectables, to meet complex therapeutic demands. Globalization of clinical trials and manufacturing is further enhancing supply chain efficiency and market reach. All these factors are creating a robust and fast-evolving ecosystem where large molecule injectable drugs are expected to play an increasingly central role in the future of global healthcare.

SCOPE OF STUDY:

The report analyzes the Large Molecule Injectable Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Intravenous Injections, Muscle Injections, Subcutaneous Injections); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, E-Commerce End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â